CTRI/2022/03/040774CompletedPhase 2
preclinical and clinical evaluation of the effect on oral administration of POONAI MEESAI CHOORANAM KUDINEER in the management of OOTHU SOBAI
Dr P Narmatha1 site in 1 country40 target enrollmentStarted: March 3, 2022Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- REDUCTION IN SYMPTOMS
Study Overview
Brief Summary
It is single arm trails for preclinical and clinical evaluation of the effects on oral administration of poonai meesai chooranam kudineer in the management of oothu sobai
Study Design
- Study Type
- Interventional
- Allocation
- Not Applicable
- Masking
- Not Applicable
Eligibility Criteria
- Ages
- 3.00 Year(s) to 12.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Oedema due to renal impairment.
Exclusion Criteria
- •Children above 12 years Children below 3 years Hypothyroidism Cushing syndrome Oedema due to drug allergy Oedema mimics obesity in children Acute glomerular nephritis Chronic glomerular nephritis.
Outcomes
Primary Outcomes
REDUCTION IN SYMPTOMS
Time Frame: 21 days
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Preclinical and clinical evaluation of the effect of Siddha classical drug PARUMA NOI NIVARANA MAATHIRAI & NEERMULLI OORAL KUDINEER (oral administration ) along with PODI THIMIRTHAL ( external therapy) in the management of CHILDHOOD OBESITY.CTRI/2022/02/040297Dr J Mangalavalli40
Completed
Phase 1
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941Liver DiseaseNCT01187186Astellas Pharma Inc16
Completed
Phase 1
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy VolunteersHealthyNCT01002963Pfizer56
Terminated
Phase 1
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy SubjectsHealthy VolunteersImpaired Renal FunctionNCT04252430MedDay Pharmaceuticals SA24
Terminated
Phase 1
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy SubjectsHealthy VolunteersHepatic Impairment of Moderate Child Pugh CategoryNCT04252417MedDay Pharmaceuticals SA15
